Neoadjuvant therapy for pancreatic cancer
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …
surgical resection of the primary tumour and systemic chemotherapy, which provides …
Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis
ZJ Brown, V Heh, HE Labiner, GN Brock… - British Journal of …, 2023 - academic.oup.com
Background Neoadjuvant therapy is increasingly being used before surgery for localized
pancreatic cancer. Given the importance of completing multimodal therapy, the aim of this …
pancreatic cancer. Given the importance of completing multimodal therapy, the aim of this …
Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial
DPS Sohal, M Duong, SA Ahmad, NS Gandhi… - JAMA …, 2021 - jamanetwork.com
Importance Clinical outcomes after curative treatment of resectable pancreatic ductal
adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of …
adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of …
[HTML][HTML] Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic …
T Seufferlein, W Uhl, M Kornmann, H Algül, H Friess… - Annals of …, 2023 - Elsevier
Background Data on perioperative chemotherapy in resectable pancreatic ductal
adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant …
adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant …
Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. Pooled data from 3 randomized controlled trials
Objective: The aim of this study was to pool data from randomized controlled trials (RCT)
limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a …
limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a …
Anticancer nanotherapeutics in clinical trials: The work behind clinical translation of nanomedicine
A Parodi, EP Kolesova, MV Voronina… - International Journal of …, 2022 - mdpi.com
The ultimate goal of nanomedicine has always been the generation of translational
technologies that can ameliorate current therapies. Cancer disease represented the primary …
technologies that can ameliorate current therapies. Cancer disease represented the primary …
Neoadjuvant therapy for pancreatic cancer
J Gugenheim, A Crovetto, N Petrucciani - Updates in surgery, 2022 - Springer
Multimodal treatment including surgery and chemotherapy is considered the gold standard
treatment of pancreatic cancer by most guidelines. Neoadjuvant therapy (NAT) has been …
treatment of pancreatic cancer by most guidelines. Neoadjuvant therapy (NAT) has been …
A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (hyperacute-pancreas) immunotherapy in subjects with borderline resectable or …
Objectives: To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas
algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care …
algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care …
Neoadjuvant immunotherapy for localized pancreatic cancer: Challenges and early results
Simple Summary Pancreatic cancer is a deadly disease with limited effective treatments.
Despite growing interest in immunotherapy for other cancer types, immunotherapy has not …
Despite growing interest in immunotherapy for other cancer types, immunotherapy has not …
Preoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy
Despite recent advances in the systemic treatment of gastrointestinal tumors, pancreatic
adenocarcinoma (PDAC) remains a challenging disease, with 5‐year survival just over 10 …
adenocarcinoma (PDAC) remains a challenging disease, with 5‐year survival just over 10 …